SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Craig Markell who wrote (4468)6/5/1998 10:31:00 AM
From: biodoc  Read Replies (1) | Respond to of 7041
 
I wonder if anyone knows what was presented regarding the statistical analysis of the trials which are being quoted. What was the p value for the effect in the 40 mg group? My take on it is that the 80 mg dose doesn't stand a chance because of several men failing the challenge test with chest pain or significant hypotension. Unless the p value with the lower dose (40 mg) is good (and my guess it is marginal at best) I don't think the drug has a chance of being approved, given the marginal observed clinical efficacy. This information must have been presented--does anyone know it?



To: Craig Markell who wrote (4468)6/5/1998 12:02:00 PM
From: Linda Kaplan  Respond to of 7041
 
Craig, It just doesn't sound like Vasomax is much more effective than a placebo, it only works on people with minimal problems when it works at all, and it's been said that the test results may be better than performance in real life. Plus there's a fair chance it won't be approved at all. Plus there are so many other drugs in the wings that sound better.

Linda


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News